Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 19/20 | 0.86 |
| ▸ | ESR2 | Q92731 | 16/20 | 0.69 |
| ▸ | MEN1 | O00255 | 2/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.65 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.65 |
| ▸ | PLD2 | O14939 | 1/20 | 0.61 |
| ▸ | KDM1A | O60341 | 1/20 | 0.61 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.61 |
| ▸ | USP2 | O75604 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | C5 | P01031 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | TP53 | P04637 | 1/20 | 0.61 |
| ▸ | FYN | P06241 | 1/20 | 0.61 |
| ▸ | PGR | P06401 | 1/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.61 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7104864 | 0.93 | ESR1 (1.00) | ESR1ESR2MEN1KMT2ATDP1 | |
| SCHEMBL8631942 | 0.93 | ESR1 (0.81) | ESR1ESR2MEN1KMT2ATDP1 | |
| SCHEMBL8562371 | 0.93 | ESR1 (0.76) | ESR1ESR2MEN1KMT2ATDP1 | |
| SCHEMBL8626952 | 0.93 | ESR1 (0.80) | ESR1ESR2MEN1KMT2ATDP1 | |
| SCHEMBL31683627 | 0.93 | ESR1 (0.81) | ESR1ESR2MEN1KMT2ATDP1 | |
| SCHEMBL11552368 | 0.92 | ESR1 (0.75) | ESR1ESR2MEN1KMT2ATDP1 | |
| SCHEMBL7107598 | 0.92 | ESR1 (0.75) | ESR1ESR2MEN1KMT2ATDP1 | |
| SCHEMBL25079639 | 0.90 | ESR1 (0.81) | ESR1ESR2MEN1KMT2ATDP1 | |
| SCHEMBL14527573 | 0.89 | ESR1 (0.74) | ESR1ESR2MEN1KMT2ATDP1 | |
| SCHEMBL8628060 | 0.89 | ESR1 (0.74) | ESR1ESR2MEN1KMT2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116332901-B | Raloxifene derivative with room temperature phosphorescence characteristic and application thereof | 华东理工大学 | 2025-02-25 | — | — | CN | claimed |
| CN-116332901-A | Raloxifene derivative with room temperature phosphorescence characteristic and application thereof | 华东理工大学 | 2023-06-27 | — | — | CN | claimed |
| EP-0920863-B1 | The use of 2-Aryl-3-aroylbenzo(b)thiophenes for the treatment of estrogen deprivation syndrome | LILLY CO ELI (US) | 2003-07-09 | — | — | EP | claimed |
| US-6156786-A | ANTIESTROGENS | ELI LILLY AND COMPANY (US) | 2000-12-05 | — | — | US | claimed |
| EP-0920863-A1 | 2-Aryl-3-aroylbenzo(b)thiophenes useful for the treatment of estrogen deprivation syndrome | ELI LILLY AND COMPANY (US) | 1999-06-09 | — | — | EP | claimed |
| WO-1999025706-A1 | 2-ARYL-3-AROYLBENZO[B]THIOPHENES USEFUL FOR THE TREATMENT OF ESTROGEN DEPRIVATION SYNDROME | ELI LILLY AND COMPANY (US) | 1999-05-27 | — | — | WO | claimed |
| CN-116332901-B | Raloxifene derivative with room temperature phosphorescence characteristic and application thereof | 华东理工大学 | 2025-02-25 | — | — | CN | disclosed |
| CN-116332901-A | Raloxifene derivative with room temperature phosphorescence characteristic and application thereof | 华东理工大学 | 2023-06-27 | — | — | CN | disclosed |
| EP-2314581-B1 | A process for preparing benzo[b]thiophene derivatives | HEXAL AG (DE) | 2012-07-25 | — | — | EP | disclosed |
| WO-2011047877-A1 | A PROCESS FOR PREPARING BENZO[B]THIOPHENE DERIVATIVES | HEXAL AKTIENGESELLSCHAFT (DE) | 2011-04-28 | — | — | WO | disclosed |
| EP-2314581-A1 | A process for preparing benzo[b]thiophene derivatives | Hexal AG (DE) | 2011-04-27 | — | — | EP | disclosed |
| EP-0920863-B1 | The use of 2-Aryl-3-aroylbenzo(b)thiophenes for the treatment of estrogen deprivation syndrome | LILLY CO ELI (US) | 2003-07-09 | — | — | EP | disclosed |
| US-20020173645-A1 | Non-solvated crystalline 6-hydroxy-2- (4-hydroxyphenyl) -3- [4- (2-piperidinoethoxy) benzoyl] benzo [b] thiophene hydrochloride | LUKE WAYNE DOUGLAS (US) | 2002-11-21 | — | — | US | disclosed |
| US-5731327-A | Synthesis of 3- 4-(2-aminoethoxy)benzoyl!-2-aryl-6-hydroxybenzo b!thiophenes | ELI LILLY AND COMPANY (US) | 1998-03-24 | — | — | US | disclosed |
| WO-1996009045-A1 | ANTIESTROGENIC BENZOTHIOPHENYL COMPOUNDS | ELI LILLY AND COMPANY (US) | 1996-03-28 | — | — | WO | disclosed |
| EP-0629697-A2 | Materials and methods for screening anti-osteoporosis agents | ELI LILLY AND COMPANY (US) | 1994-12-21 | — | — | EP | disclosed |
| EP-0541475-A1 | Automatic dishwashing composition | CLEANTABS A/S (DK) | 1993-05-12 | — | — | EP | disclosed |
| EP-0508934-A1 | A laundry detergent composition | CLEANTABS A/S (DK) | 1992-10-14 | — | — | EP | disclosed |
| EP-0504091-A1 | A phosphate-free automatic dishwashing composition | CLEANTABS A/S (DK) | 1992-09-16 | — | — | EP | disclosed |
| US-4133814-A | ANTITUMOR AGENTS | ELI LILLY AND COMPANY (US) | 1979-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020173645-A1 | Non-solvated crystalline 6-hydroxy-2- (4-hydroxyphenyl) -3- [4- (2-piperidinoethoxy) benzoyl] benzo [b] thiophene hydrochloride | HTR3B, HTR3C, HTR2B | ESR1 4320/4885ESR2 4181/4885MEN1 4881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.